Copley Scientific is widely recognised as the world’s leading manufacturer of orally inhaled and nasal drug product (OINDP) test equipment and a trusted global provider of testing systems for other pharmaceutical dosage forms, including tablets, capsules, transdermals, semisolids, powders and granules. Founded in 1946 in Nottingham, UK, the Company continues to work closely with industry groups and leading experts to bring relevant new products to market, with all equipment backed by expert training and lifetime support. Copley supplies precision-engineered systems to support the everyday testing of: OINDP in vitro Testing Tablet & Capsule Disintegration Tablet & Capsule Dissolution Tablet Friability Tablet Hardness Powder Flowability Powder Bulk and Tapped Density Semisolids Testing Suppository Testing Tablet Thickness Testing Used from R&D through to QC, this extensive range of equipment is supported by a full validation and aftersales service. We deliver pharmaceutical testing equipment with the necessary accuracy and reproducibility hardwired into its design by adopting the same Quality by Design principles that our customers rely on to control product performance. Continuous improvement is a core element of this approach and we strive to exceed the expectations of the industry, not only by enhancing equipment performance but also through unrivalled service. Copley has offices in the UK and Switzerland and works with specialist distributors extending localised support across the world. This network provides expert help and training to every customer, directly enhancing the application of all Copley products. Committed to excellence, we always aim to deliver the right service outcomes efficiently and provide an outstanding customer experience.
A significant number of procedures performed during inhaler testing are highly repetitive and their performance can lead to bottlenecks which compromise overall laboratory operations and efficiency. Relatively simple and inexpensive sample recovery tools have been designed to alleviate such problems and to ensure testing is carried out in a consistent, reproducible and controlled fashion. The NGI Gentle Rocker, for examp…
In 1997, a group of prominent pharmaceutical companies came together in the form of a consortium with the express intent of developing a new impactor specifically for inhaled and nasal products. The result, the Next Generation Impactor (NGI), was launched in 2000 and subsequently accepted into the Pharmacopoeias in 2005. The NGI has seven stages, five of which are in the range 0.5 to 5 microns plus a micro-orifice collector w…
